dase patway in endothelial cells. Vascul Pharmacol 2006;44:143-148 22. Feng M, Liu L, Guo Z, Xiong Y. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/ NO pathway in endothelial cells induced by lysophosphatidylcholine. Eur J Pharmacol 2008;584:4956 23. takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. Lysophosphatidylcholine induces apoptosis in human endotelial cells through a p38mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 2002;161:387-394 24. Park S, Kim JA, Choi S, Suh SH. Superoxide is a potential culprit of caspase-3 dependent endothelial cell death induced by lysophosphatidylcholine. J Physiol Pharmacol 2010;61:375-381 25. Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA Journal 2011;2:27-38 26. The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:15361544
Revista de la ALAD
V1 NÂş2
27. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56:e50-e103
66
28. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2011;42:517-584 29. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel
recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101(suppl):51F-57F 30. Corson MA. Darapladib: an emerging therapy for atherosclerosis. Ther Adv Cardiovasc Dis 2010;4:241-248 31. McCullough PA. Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr Atheroscler Rep 2009;11:334-337 32. Epps KC, Wilensky RL. Lp-PLA2 – a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 2011;269:94-106